Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics

Journal of Pharmaceutical Sciences

Volumn 95, Issue 4, 2006, Pages 883-895

  Eichenbaum, G ^a   Pollock Dove, C ^c   Nguyen, J ^c   Li, S ^c   Evans, J ^c   Borghys, H ^b   Kennis, L ^b   Dong, L ^c   Van Osdol, W ^c   Dai, W ^c   Scicinski, J ^c   Chen, J ^c   Xu, Y ^c   Ashton, D ^b   Mackie, C ^b   Megens, A ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c ALZA CORPORATION   (United States)

Author keywords

ADME; Colonic drug delivery; Intestinal absorption; Oral absorption; Pharmacokinetics; Site specific absorption; Site specific delivery

Indexed keywords

APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; JNJ 16514537; JNJ 16558711; JNJ 16601650; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DATA ANALYSIS; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; EXPERIMENTAL MODEL; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; MASS SPECTROMETRY; NONHUMAN; PERMEABILITY; RAT; VOMITING;

EID: 33646024344     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20550     Document Type: Article

References (36)

1. Vetrovec GW, Parker VE, Cole S, Procacci PM, Tabatznik B, Terry R. 1987. Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine. Am J Med 83:24-29.
2. Sathyan G, Chancellor MB, Gupta SK. 2001. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 52:409-417.
3. Robinson JR, Lee VHL, editors. 1987. Controlled drug delivery: Fundamentals and applications. 2nd edition, New York: Marcel Dekker, Inc. p 716.
4. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S. 2003. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204-211.
5. Mrhar A, Bogataj M, Grabnar I, Karba R. 1999. Formulation of controlled release microspheres containing nicardipine: The role of pharmacokinetic modeling and computer simulation. Eur J Drug Metab Pharmacokinet 24:55-61.
6. Chaubal MV. 2004. Application of drug delivery technologies in lead candidate selection and optimization. Drug Discov Today 9:603-609.
7. Horspool KR, Lipinski CA. 2003. Advancing new drug delivery concepts to gain the lead. Drug Deliv Technol 3:34-46.
8. Ritschel W. 1989. Biopharmaceutic and Biopharmacokinetc Aspects in the Design of Controlled Release Peroral Drug Delivery Systems. Drug Dev Ind Pharm 15:1073-1103.
9. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. 1987. Simplified assessment of segmental colonic transit. Gastroenterology 92:40-47.
10. Barrow L, Steed KP, Spiller RC, Watts PJ, Melia CD, Davies MC, Wilson CG. 1992. Scintigraphic demonstration of lactulose-induced accelerated proximal colon transit. Gastroenterology 103:1167-1173.
11. Gruber P, Longer M, Robinson J. 1987. Some biological issues in oral, controlled drug delivery. Adv Drug Deliv Rev 1:1-18.
12. Jezyk N, Rubas W, Grass G. 1992. Permeability characteristics of various intestinal regions of rabbit, dog, and monkey. Pharm Res 9:1580-1586.
13. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, Lennernas H. 1998. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 87:360-366.
14. Fagerholm U, Lindahl A, Lennernas H. 1997. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol 49:687-690.
15. Lee L, M H, Y W, G S. 2004. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. J Clin Pharmacol 44:599-604.
16. Artursson P, Ungell AL, Lofroth JE. 1993. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
17. Boisset M, Botham RP, Haegele KD, Lenfant B, Pachot JI. 2000. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: Importance of drug ionisation in the in vitro prediction of in vivo absorption. Eur J Pharm Sci 10:215-224.
18. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. 2002. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129-1134.
19. Clemens JA, Smalstig EB, Sawyer BD. 1974. Antipsychotic drugs stimulate prolactin release. Psychopharmacologia 40:123-127.
20. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
21. Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K. 2001. Optimized conditions of biomimetic artificial membrane permeation assay. Int J Pharm 228:181-188.
22. Niemegeers C, Janssen P. 1979. A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24:2201-2216.
23. Niemegeers CJE. 1982. Antiemetic specificity of dopamine antagonists. Psychopharmacologia 78:210-213.
24. Finney DJ. 1962. Probit analysis, ed., Cambridge, England: Cambridge University Press.
25. ALZA. Corporation, unpublished data.
26. Avdeef A. 2003. Absorption and drug development: solubility, permeability, and charge state. 1st edition, Hoboken, New Jersey: John Wiley & Sons. p 287.
27. Sugano K, Takata N, Machida M, Saitoh K, Terada K. 2002. Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int J Pharm 241:241-251.
28. Curatolo W. 1998. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Science Tech Today 1(9):387-393.
29. Ezewuzie N, Taylor D. 2005. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 20(1): 86-90.
30. DeSesso JM, Jacobson CF. 2001. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 39:209-228.
31. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89:429-442.
32. Chiou WL, Robbie G, Chung SM, Wu TC, Ma C. 1998. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: Mean allometric coefficient of 0.66. Pharm Res 15:1474-1479.
33. Chiou WL, Barve A. 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-1795.
34. ALZA. Corporation, unpublished data.
35. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. 1993. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21:1134-1141.
36. Fang J, Bourin M, Baker GB. 1999. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147-151.